The proprietary NxGen microfluidic mixer enables the reproducible scale-up of mRNA lipid nanoparticles by preserving the critical conditions at the point of formulation.
PNI is globally renowned for their NanoAssembr suite of products that enable high quality, consistent nanoparticle formation and seamless scale up from the laboratory to GMP manufacturing for the clinic. Using their GMP System will let us meet the challenge of producing our pan-coronavirus DNA vacci...Read More
Chief Executive Officer
We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens.
Director of Initiative for RNA
Harvard Medical School
Our team has been dedicated to developing safe and effective vaccines to fight against the COVID-19 pandemic. Since RNA vaccines are a disruptive technology as they do not require cell culture, utilize synthetic delivery and have a smaller manufacturing footprint, our partnership with PNI to advanc...Read More
Co-founder, Chairman and CEO
Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure that Canada has modern, flexible vaccine manufacturing capabilities now and in the future. With the investments announced today, our government is helping Canadian...Read More
Minister of Innovation, Science and Industry
Government of Canada
The scalability and reproducibility of PNI’s NanoAssemblr platform allowed us to move into GMP manufacturing with greater control over the process and increased precision in the final product compared to our previous macromixing process, allowing acceleration of our time to commercialization.
Chief Scientific Officer
The ease, reproducibility, and the robustness of PNI’s products is amazing compared to what we previously had used, and that’s been a real enabling factor for Guide as we’ve continued to grow over the last year and a half.
Chief Technology Officer
eTheRNA used the NanoAssemblr® NxGen technology because we could perform precise tuning of the size of our nanoparticles to target the optimal immunogenicity in vivo.
Vice President of Manufacturing
Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture ...Read More
Vice President and Head of US Operations
Ajinomoto Bio-Pharma Services
In terms of ease of operation it almost doesn’t compare. The Ignite is really, really smooth. It genuinely takes about half the time to make the same subset of particles when we’re using the same machines (NABT and Ignite). It really does feel like the benchtop came out, it was out for a few years, ...Read More
Sr. Research Associate